Education/Credentials Fellowship: University of Nebraska (Rheumatology)Residency: Creighton University (Internal Medicine )Residency: LNR Foundation School (General Practice )Residency: Delhi University (Dermatology )Bachelor's Degree: Maulana Azad Medical College (Medicine and Surgery) Board Certifications & LicensesAmerican Board of Internal Medicine (Rheumatology) (Certification Date: 2016-10-13)American Board of Internal Medicine (Certification Date: 2012-08-15) - (Recertification Date: 2023-01-01) SpecialtiesInternal MedicineRheumatology Contact Information Medical Sciences Building Office 513-558-4701 Email vashispa@ucmail.uc.edu Clinical Interests Internal MedicineAnkylosing SpondylitisAutoimmune VasculitisBehcet Syndrome (Neuro-Bechet)Central Nervous System Lupus VasculitisCollagen DiseaseCREST SyndromeCryoglobulinemiaCutaneous, Leukocytoclastic, VasculitisGoutHip Rheumatoid ArthritisLupus (Systemic lupus erythematosus)Lupus Erythematosus PanniculitisLupus NephritisMicroscopic PolyangiitisMixed Connective Tissue Disease (MCTD)Osteochondritis DissecansOverlap Connective Tissue DiseasePaget DiseasePolymyalgia RheumaticaPolymyositisPolymyositis/DermatomyositisPseudogoutPsoriatic ArthritisRaynaud Phenomenon in SclerodermaRaynaud's DiseaseReactive Arthritis (Reiter's Syndrome)Rheumatoid ArthritisRheumatoid VasculitisStill's DiseaseSystemic Lupus Erythematosus (SLE)Systemic VasculitisTakayasu ArteritisTemporal Arteritis (Giant cell arteritis)Vasculitis (Angiitis)Weill-Marchesani Syndrome Peer Reviewed Publications Onuorah, Nneoma; Abraham, Hrudya; Vashisht, Priyanka 2020. The Diagnostic Conundrum of Felty Syndrome and T-Cell Large Granular Lymphocytic Leukemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, , Vashisht, Priyanka; O'dell, James 2017. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert opinion on biological therapy, 17 8, 989-999Vashisht P.;Sayles H.;Cannella A.;Mikuls T.;Michaud K. 10-01-2016. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials Arthritis Care and Research, 68 10, 1478-1488Wampler Muskardin T.;Vashisht P.;Dorschner J.M.;Jensen M.A.;Chrabot B.S.;Kern M.;Curtis J.R.;Danila M.I.;Cofield S.S.;Shadick N.;Nigrovic P.A.;St Clair E.W.;Bingham C.O.;Furie R.;Robinson W.;Genovese M.;Striebich C.C.;O'Dell J.R.;Thiele G.M.;Moreland L.W.;Levesque M.;Bridges S.L.;Gregersen P.K.;Niewold T.B. 10-01-2016. Increased pretreatment serum IFN-?/? ratio predicts non-response to tumour necrosis factor ? inhibit Annals of the rheumatic diseases, 75 10, 1757-1762Vashisht P.;Borghoff K.;O'Dell J.;Hearth-Holmes M. 07-01-2017. Belimumab for the treatment of recalcitrant cutaneous lupus Lupus, 26 8, 857-864Vashisht P.;Casale T. 01-01-2013. Omalizumab for treatment of allergic rhinitis Expert Opinion on Biological Therapy, 13 6, 933-945
Clinical Interests Internal MedicineAnkylosing SpondylitisAutoimmune VasculitisBehcet Syndrome (Neuro-Bechet)Central Nervous System Lupus VasculitisCollagen DiseaseCREST SyndromeCryoglobulinemiaCutaneous, Leukocytoclastic, VasculitisGoutHip Rheumatoid ArthritisLupus (Systemic lupus erythematosus)Lupus Erythematosus PanniculitisLupus NephritisMicroscopic PolyangiitisMixed Connective Tissue Disease (MCTD)Osteochondritis DissecansOverlap Connective Tissue DiseasePaget DiseasePolymyalgia RheumaticaPolymyositisPolymyositis/DermatomyositisPseudogoutPsoriatic ArthritisRaynaud Phenomenon in SclerodermaRaynaud's DiseaseReactive Arthritis (Reiter's Syndrome)Rheumatoid ArthritisRheumatoid VasculitisStill's DiseaseSystemic Lupus Erythematosus (SLE)Systemic VasculitisTakayasu ArteritisTemporal Arteritis (Giant cell arteritis)Vasculitis (Angiitis)Weill-Marchesani Syndrome
Peer Reviewed Publications Onuorah, Nneoma; Abraham, Hrudya; Vashisht, Priyanka 2020. The Diagnostic Conundrum of Felty Syndrome and T-Cell Large Granular Lymphocytic Leukemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, , Vashisht, Priyanka; O'dell, James 2017. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert opinion on biological therapy, 17 8, 989-999Vashisht P.;Sayles H.;Cannella A.;Mikuls T.;Michaud K. 10-01-2016. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials Arthritis Care and Research, 68 10, 1478-1488Wampler Muskardin T.;Vashisht P.;Dorschner J.M.;Jensen M.A.;Chrabot B.S.;Kern M.;Curtis J.R.;Danila M.I.;Cofield S.S.;Shadick N.;Nigrovic P.A.;St Clair E.W.;Bingham C.O.;Furie R.;Robinson W.;Genovese M.;Striebich C.C.;O'Dell J.R.;Thiele G.M.;Moreland L.W.;Levesque M.;Bridges S.L.;Gregersen P.K.;Niewold T.B. 10-01-2016. Increased pretreatment serum IFN-?/? ratio predicts non-response to tumour necrosis factor ? inhibit Annals of the rheumatic diseases, 75 10, 1757-1762Vashisht P.;Borghoff K.;O'Dell J.;Hearth-Holmes M. 07-01-2017. Belimumab for the treatment of recalcitrant cutaneous lupus Lupus, 26 8, 857-864Vashisht P.;Casale T. 01-01-2013. Omalizumab for treatment of allergic rhinitis Expert Opinion on Biological Therapy, 13 6, 933-945
Onuorah, Nneoma; Abraham, Hrudya; Vashisht, Priyanka 2020. The Diagnostic Conundrum of Felty Syndrome and T-Cell Large Granular Lymphocytic Leukemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, , Vashisht, Priyanka; O'dell, James 2017. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert opinion on biological therapy, 17 8, 989-999Vashisht P.;Sayles H.;Cannella A.;Mikuls T.;Michaud K. 10-01-2016. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials Arthritis Care and Research, 68 10, 1478-1488Wampler Muskardin T.;Vashisht P.;Dorschner J.M.;Jensen M.A.;Chrabot B.S.;Kern M.;Curtis J.R.;Danila M.I.;Cofield S.S.;Shadick N.;Nigrovic P.A.;St Clair E.W.;Bingham C.O.;Furie R.;Robinson W.;Genovese M.;Striebich C.C.;O'Dell J.R.;Thiele G.M.;Moreland L.W.;Levesque M.;Bridges S.L.;Gregersen P.K.;Niewold T.B. 10-01-2016. Increased pretreatment serum IFN-?/? ratio predicts non-response to tumour necrosis factor ? inhibit Annals of the rheumatic diseases, 75 10, 1757-1762Vashisht P.;Borghoff K.;O'Dell J.;Hearth-Holmes M. 07-01-2017. Belimumab for the treatment of recalcitrant cutaneous lupus Lupus, 26 8, 857-864Vashisht P.;Casale T. 01-01-2013. Omalizumab for treatment of allergic rhinitis Expert Opinion on Biological Therapy, 13 6, 933-945